MCM
ENTA icon

Moore Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Moore Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-71,586
Closed -$4.42M – 201
2019
Q4 		$4.42M Buy
71,586
+53,161
+289% +$3.3M 0.14% 148
2019
Q3 		$1.11M Buy
+18,425
New +$1.37M 0.04% 233

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Moore Capital Management's ENTA Position: Q1 2020 in Review

Moore Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 71,586 shares — an estimated $4.42M sold.

Moore Capital Management first reported a position in ENTA in Q3 2019 and held it in 2 quarters. The position peaked at $4.42M in Q4 2019. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

  • Moore Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Moore Capital Management sold 71,586 Enanta Pharmaceuticals shares in Q1 2020, an estimated $4.42M.
  • Moore Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Moore Capital Management's Enanta Pharmaceuticals position peaked at $4.42M in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Moore Capital Management's 13F filing for Q1 2020, filed 15 May 2020.